Melanie Janning
Dr. med.
Melanie Janning
  • Working area 1
German (Mother tongue)

Areas of expertise


  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2011

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, Schatz S, Falk M, Berger L, Böttcher L, Päsler S, Gorges T, O'Flaherty L, Hille C, Joosse S, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S
CANCERS. 2019;11(6):.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Berger L, Janning M, Velthaus J, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S
J THORAC ONCOL. 2018;13(12):e243-e246.

Anti-Angiogenics: Their Value in Lung Cancer Therapy
Janning M, Loges S
ONCOL RES TREAT. 2018;41(4):172-180.

Management immunvermittelter Nebenwirkungen - CME Fortbildung
Janning M, Loges S
hautnah Dermatologie. 2018;34(1):38-46.

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)
Krauter J, Fiedler W, Schlenk R, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik V, Becker H, Greil C, Reimer P, Götze K, Döhner H, Ganser A, Heuser M
BRIT J HAEMATOL. 2018;183(2):235-241.

Zielgerichtete Therapie und Immuntherapie bei der AML
Janning M, Fiedler W
J Onkol - Z Onkol Fortb. 2017;5(05):184-191.

Management immunvermittelter Nebenwirkungen - CME Fortbildung
Janning M, Loges S
InFo Onkologie. 2017;20(S1):54-64.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S
NAT COMMUN. 2017;8(1):269.

Akute Myeloische Leukämie.
Fiedler W, Janning M
Aktuelle Gesundheitsnachrichten . 2016.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk R

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M, Ben-Batalla I, Loges S
Expert Rev Hematol. 2015;8(2):135-8.

Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3)
Rouka E, Simister P, Janning M, Kumbrink J, Konstantinou T, Muniz J, Joshi D, O'Reilly N, Volkmer R, Ritter B, Knapp S, von Delft F, Kirsch K, Feller S
J BIOL CHEM. 2015;290(42):25275-92.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Akute myeloische Leukämie –bestmögliche Behandlung.
Fiedler W, Janning M, Kebenko M, Weidmann J, Janjetovic S, Bokemeyer C
Hamb Ärztebl. 2014;68:11-17.

Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development
Janning M, Fiedler W
FUTURE ONCOL. 2014;10(7):1157-65.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Janjetovic S, Bacher U, Haalck T, Janning M, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2013;129(2):121-125.

Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature
Janjetovic S, Janning M, Daukeva L, Bokemeyer C, Fiedler W
TUMORI . 2013;99(3):e96-9.

Relevant bleeding diathesis due to acquired factor XIII deficiency
Janning M, Holstein K, Spath B, Schnabel C, Bannas P, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2013;33 Suppl 1:S50-4.

Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z, Doondeea J, Gholami A, Janning M, Lemeer S, Kramer K, Eccles S, Gollin S, Grenman R, Walch A, Feller S, Kuster B
MOL CELL PROTEOMICS. 2011;10(12):11635.

Letzte Aktualisierung aus dem FIS: 13.11.2019 - 06:17 Uhr